<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The human recombinant GM-CSF (hrGM-CSF) is a glycosylated hematopoietic growth factor, derived from <z:chebi fb="0" ids="29327">CHO</z:chebi> cells (Schering Plough/Sandoz) used in these studies </plain></SENT>
<SENT sid="1" pm="."><plain>The hrGM-CSF can be given intravenously (i.v.) in 4- to 24-h infusions or subcutaneously (scx) once or twice a day </plain></SENT>
<SENT sid="2" pm="."><plain>Many patients (more than a thousand) have been treated with the hrGM-CSF in various pathologies, in association with anti-<z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> chemotherapy, after bone marrow transplants or for <z:hpo ids='HP_0002863'>myelodysplasias</z:hpo>, <z:hpo ids='HP_0005505'>refractory anemias</z:hpo>, some <z:hpo ids='HP_0001875'>neutropenias</z:hpo> and <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>The reversion of <z:hpo ids='HP_0001875'>neutropenia</z:hpo> is dose-dependent with either a sc or i.v. administration </plain></SENT>
<SENT sid="4" pm="."><plain>Recommended doses are from 5.0 to 10.0 micrograms/kg/per day </plain></SENT>
<SENT sid="5" pm="."><plain>When the product is given sc the effect is delayed by one day but is more prolonged than with the i.v. route </plain></SENT>
<SENT sid="6" pm="."><plain>The treatment duration has been investigated in different studies: a minimal duration of 5 days seems appropriate </plain></SENT>
<SENT sid="7" pm="."><plain>When given in association with high doses of cytotoxic chemotherapeutic agents 10 to 14 days are required </plain></SENT>
<SENT sid="8" pm="."><plain>In bone marrow transplants (autologous or allogenic with T-cell <z:mpath ids='MPATH_63'>depletion</z:mpath>), the hrGM-CSF has been shown to significantly reduce the time necessary for engraftment </plain></SENT>
<SENT sid="9" pm="."><plain>Contrary to some fears, it was not shown that hrGM-CSF increased the risk of blastic transformation in <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> </plain></SENT>
<SENT sid="10" pm="."><plain>In association with <z:chebi fb="1" ids="16040">cytosine</z:chebi>-<z:chebi fb="0" ids="22601">arabinoside</z:chebi> a certain number of partial and complete responses have been obtained </plain></SENT>
<SENT sid="11" pm="."><plain>The toxic effects of the product are also dose-dependent </plain></SENT>
<SENT sid="12" pm="."><plain>At doses greater than 11 micrograms/kg per day, there is a risk of stimulating inflammatory phenomena whereas at lower doses, more moderate side effects (<z:hpo ids='HP_0003326'>myalgia</z:hpo>, <z:hpo ids='HP_0001945'>fever</z:hpo>, injection site reaction) occur in only 30% of the cases </plain></SENT>
<SENT sid="13" pm="."><plain>The GM-CSF will certainly be important in the future in haematology, <z:hpo ids='HP_0002664'>oncology</z:hpo> and for the treatment of <z:e sem="disease" ids="C0009450" disease_type="Disease or Syndrome" abbrv="">infectious diseases</z:e> </plain></SENT>
</text></document>